Table 3.
Risk of developing venous thromboembolism in a year according to the European Medicines Agency [European Medicines Agency, 2013].
| Women not using a combined hormonal | |
| pill/patch/ring and are not pregnant | About 2 out of 10,000 women |
| Women using a combined hormonal | |
| contraceptive (CHC) containing | |
| levonorgestrel, norethisterone or norgestimate | About 5–7 out of 10,000 women |
| Women using a CHC containing | |
| etonogestrel or norelgestromin | About 6–12 out of 10,000 women |
| Women using a CHC containing | |
| drospirenone, gestodene or desogestrel | About 9–12 out of 10,000 women |
| Women using a CHC containing | |
| chlormadinone, dienogest or nomegestrol | Not yet known1 |
1
Further studies are ongoing or planned to collect sufficient data to estimate the risk for these products.